Dr. Adam Ruskin has over 30 years of experience leading all clinical trial operational activities for primarily early-stage companies including one that conducted a successful IPO and four that were acquired due to conducting successful clinical results. These included an infectious disease company, Cerexa Inc., purchased by Forest Laboratories to acquire the first FDA-approved therapeutic for the treatment of MRSA. Prior to moving into the biopharmaceutical industry, Dr. Ruskin was an epidemiologist with the Centers for Disease Control (CDC) and with the Grady Hospital system in Atlanta where he worked on the first FDA-approved treatment for HIV/AIDS. Dr. Ruskin then led the clinical operations department for UCSF’s non-profit CRO before co-founding a CRO focusing on early-stage San Francisco Bay area biotechnology companies.
Additional accomplishments include, leading the clinical operations for Moderna’s Phase 3 COVID-19 vaccine (the largest successful US-only clinical trial), the first FDA-cleared multiplexed sample-to-answer PCR test, and the first FDA-cleared diagnostic tests for any kind of leukemia and autism. Dr. Ruskin is also a leading industry speaker in clinical operations integration with data management and remote clinical trials. Dr. Ruskin attended Kansas State University graduating with a DVM in Veterinary Medicine, Emory University graduating with a PhD in Epidemiology, and Pennsylvania State University achieving honors degrees in both Animal Bioscience and Environmental Resource Management.